TAARs (trace amine-associated receptors) are G-protein-coupled receptors that respond to low abundance, endogenous amines such as tyramine and tryptamine, and represent potential targets for neuropsychiatric diseases. However, some members of this receptor subfamily either have no ligand identified or remain difficult to express and characterize using recombinant systems. In the present paper we report the successful expression of human and mouse TAAR1, and the characterization of their responses to various natural and synthetic agonists. In HEK (human embryonic kidney)-293/CRE-bla cells, mouse TAAR1 showed a robust response to trace amines as measured using either a cAMP assay or a β-lactamase reporter assay, whereas human TAAR1 showed a weaker, but still measurable, response. When certain fragments of human TAAR1 were replaced with the corresponding regions of mouse TAAR1, the chimaeric receptor showed a much stronger response in cAMP production. Examination of a series of agonists on these receptors revealed that the human and the chimaeric receptor are almost identical in pharmacology, but distinct from the mouse receptor. We also screened small libraries of pharmacologically active agents on TAAR1 and identified a series of synthetic agonists, some of which are also ligands of the enigmatic imidazoline receptor. The findings of the present study not only shed light on the pharmacological species difference of TAAR1, but also raise new possibilities about the mechanism of some of the imidazolinerelated agents.
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INTRODUCTION
Trace amines, including tyramine, tryptamine, octopamine and PEA (β-phenylethylamine), have been found in many organisms from plants, bacteria and insects to mammals [1] . These amines exist at low concentrations (0.1-10 nM, less than 1 % of total biogenic amines) in the mammalian brain [2] . In mammals, trace amines can produce amphetamine-like responses, such as increased alertness, euphoria, decreased appetite, insomnia and tremor [3] . Trace amine dysfunction has been linked to various psychiatric and neurological disorders, including schizophrenia and Parkinson's disease. In addition, their potential roles in other conditions, such as attention-deficit hyperactivity disorder, substance abuse and eating disorders have also been suggested [4] .
The first trace amine receptor was cloned independently by two groups using degenerate amplification [5, 6] . This receptor, later designated TAAR1 (trace amine-associated receptor 1) [7, 8] , is a novel GPCR (G-protein-coupled receptor) signalling through the stimulatory G-protein (G αs ). Subsequently, a total of 53 TAAR1-related genes were identified in human, mouse, rat and chimpanzee through genome-wide sequence scanning efforts [3, 7, [9] [10] [11] . In humans, six intronless TAAR-encoding genes are clustered tightly on chromosome 6q23.2, where a susceptibility locus for schizophrenia is located [5] . But so far, only two of these human receptors (TAAR1 and TAAR4) have been reported to be activated by trace amines. Interestingly, evidence indicates that some of the TAARs may actually serve as chemosensory receptors in mammals [12] .
With regarding to TAAR1, the human receptor is 97 % identical with the chimpanzee orthologue in amino acid sequence, but only 76 % and 79 % identical with the mouse and rat receptors respectively [13] . Human TAAR1 is expressed at lowto-moderate levels in peripheral tissues, such as the stomach, kidney and lung, and in discrete regions within the central nervous system, primarily in the amygdala [6] . Mouse, rat and monkey TAAR1, on the other hand, are distributed widely throughout the brain [5, 6, 14, 15] . Taar1-knockout mice are viable, but display deficiency in prepulse inhibition, an enhanced behavioural response to amphetamine, and augmented striatal release of dopamine when compared with wild-type animals [14, 16, 17] . In the monkey, TAAR1 was found to be a modulator of the dopamine transporter [18] . Taken together, these results suggest that TAAR1 plays important roles in behavioural control and may be a potential target for the development of novel psychoactive therapeutics.
Even though TAAR1 from all species have been reported to be activated by trace amines and many other agents [5] [6] [7] 19, 20] , there are significant species differences in the pharmacology of these agents. These species differences were determined using either sequence-modified human receptors or systems with an overexpressed G α protein due to low expression levels of the human receptor [6, 19, 21] . No direct pharmacological comparison has been carried out to validate these methods. In the present paper we report the successful expression of human and mouse TAAR1 in HEK (human embryonic kidney)-293/CRE-bla cells. Using this system, we compared in detail the pharmacological profile of human, mouse and a human-mouse chimaeric TAAR1 with two distinct assays, cAMP and β-lactamase reporter assays. We also identified a few synthetic compounds as potent TAAR1 agonists. Interestingly, some of these compounds are also ligands of the enigmatic imidazoline receptor.
EXPERIMENTAL

Materials
Alexa Fluor ® 594-conjugated mouse anti-HA (haemagglutinin) antibody, HEK-293/CRE-bla cells, CCF4-AM substrate and the GeneBLAzer loading kit were from Invitrogen. AlphaScreen ® cAMP assay kit, OptiPlate-384 and ProxiPlate-384 plates were from PerkinElmer. The mammalian expression vector of pIRESpuro2, human genomic cDNA library and poly-D-lysinecoated 384-well black/clear plates were from BD Biosciences. Neurotransmitter and other small molecular compound libraries were from Biomol International. Imidazoline ligands were from Tocris. Unless otherwise specified, all cell culture reagents were from Invitrogen and all other chemicals were from Sigma.
Plasmids, stable cell lines and cell culture
The genes encoding human and mouse TAAR1 were amplified by PCR from genomic libraries and cloned into the modified pIRESpuro2 vector with in-frame sequences encoding a signal peptide (MKTIIALSYIFCLVFAD) followed by an HA epitope (YPYDVPDYA) at the N-terminus. The chimaeric human TAAR1 was constructed by a PCR ligation method using the above human and mouse TAAR1 plasmids as DNA templates. The final plasmid construct encodes a chimaeric protein of human TAAR1 with the following amino acid sequences replaced by the corresponding sequences of mouse TAAR1: N-terminus (amino acids 1-21), intracellular loop (amino acids 205-258) and Cterminus (amino acids 312-end). This chimaeric human-mouse TAAR1 (referred to as cTAAR1) was then cloned into the same modified pIRESpuro2 vector used for human and mouse TAAR1. HEK-293F cells or HEK-293/CRE-bla cells were transfected with TAAR1 plasmids using Lipofectamine TM 2000 according to the manufacturer's protocol (Invitrogen). HEK-293F cells were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) fetal bovine serum, 50 units/ml penicillin and 50 μg/ml streptomycin in a 5 % CO 2 incubator. HEK-293/CRE-bla cells were maintained in the above DMEM medium supplemented with 20 μg/ml zeocin. Stable cell lines were selected in DMEM supplemented with 0.8 μg/ml puromycin 20 h after transfection. Cells stably transfected with empty vector alone were generated by the same procedure and selected with 0.5 μg/ml puromycin.
Receptor activity assays
Intracellular cAMP levels were measured using the AlphaScreen ® cAMP kit essentially as described previously [22] . All AlphaScreen ® signals were converted into cAMP concentrations based on a cAMP standard curve fit to a sigmoidal dose-response model using Prism software (GraphPad). The β-lactamase reporter assay was carried out as previously described with minor modifications [23, 24] . Briefly, cells were seeded at 15 000 cells/well in 40 μl of FreeStyle 293 medium without any antibiotics and serum in a 384-well plate 16 h before compound addition. Cells were then stimulated with compounds at various concentrations for 5 h at 37
• C and loaded with the CCF4-AM substrate solution. The plates were incubated for 2 h in the dark with gentle rocking, and then read with an Envision Plate Reader (PerkinElmer) using the configuration recommended by the manufacturer (excitation = 409 nm; emission = 460 nm and 530 nm). Background readings of both channels from cell-free wells were subtracted from every sample. The response ratio was defined as the fold change of the emission ratio (Em460/Em530) from stimulated cells over that from unstimulated cells. All data were analysed and fit using the Prism software. The cellular response to compound stimulation was also visualized under a fluorescence microscope equipped with a long-pass filter passing both blue and green fluorescence lights.
RESULTS
Expression of human and mouse TAAR1 in HEK-293/CRE-bla cells
When human and mouse TAAR1 were stably or transiently expressed in HEK-293F or COS-1 cells, no expression was detected at the cell surface either by immunocytochemistry or by Western blot analysis, consistent with previous reports of poor expression in these cell lines [5] [6] [7] . Also, no cAMP response to trace amines was detected in these cells by direct measurement of cAMP (results not shown). Plasmids expressing the receptors were then transfected into HEK-293/CRE-bla cells, a cell line developed for transcription-based reporter enzyme assays [23] , and bulk stable cell lines were generated. Surprisingly, HEK-293/CRE-bla cells expressing either human or mouse TAAR1 showed elevated basal β-lactamase activity, as shown by the increased number of blue cells without the addition of trace amine ( Figure 1A , panels b and c). This increase in basal β-lactamase activity indicated that TAAR1 is a G αs -coupled receptor with a low level of constitutive activity, or that there were low levels of trace amines in the culture medium. When treated with the trace amine PEA at 10 μM, both human TAAR1-and mouse TAAR1-expressing cells showed a strong response to PEA stimulation ( Figure 1A , panels e and f), whereas vector cells had no response at all ( Figure 1A , panels a and d). Furthermore, when β-lactamase activity was quantified by measuring the emission ratio (Em460/Em530) using a fluorescence plate reader, mouse TAAR1 showed higher basal β-lactamase activity and a much stronger response to PEA stimulation ( Figure 1B) , consistent with the higher number of blue cells observed by microscopy. Intriguingly, both human and mouse TAAR1 expression in the HEK-293/CRE-bla cell line were still undetectable by either immunocytochemistry or by Western blot analysis.
Pharmacology of human and mouse TAAR1 towards endogenous trace amines
To further characterize human and mouse TAAR1, the responses of these two receptors to a series of trace amines were measured using the β-lactamase reporter assay. In cells stably expressing human TAAR1, strong responses were observed for several trace amines, among which PEA was the most potent with a maximum response ratio (E max ) of ∼ 2.8. The rank-order of potency (by EC 50 ) was PEA> tyramine > tryptamine > synephine = dopamine > octopamine (Figure 2A ). Mouse TAAR1-expressing cells showed a stronger response (E max = ∼ 3.2, compared with 2.8 for human TAAR1) for most of the amines tested ( Figure 2B ). The rankorder of potency of these compounds on mouse TAAR1 was PEA ∼ = tyramine > tryptamine synephine > octopamine, which is quite distinct from that of the human receptor. Histamine showed little activity on either the human or mouse receptor. Synephine, dopamine and apomorphine showed similar response curves in both human TAAR1 and vector control cells (Figure 2C ), suggesting a non-specific response. Consequently these three compounds were excluded from further studies. However, tryptamine showed a much better response in TAAR1 cells, especially in mouse TAAR1-expressing cells (EC 50 = 0.2 μM, E max = 3) than in vector cells (EC 50 = 16.5 μM, E max = 2.1), indicating some level of specific, TAAR1-mediated response. To confirm the β-lactamase reporter assay results, responses of both human and mouse TAAR1 to trace amines were also analysed by measuring cAMP directly. Human TAAR1 cells showed significant cAMP production after PEA or tyramine treatment ( Figure 3A) , with the rank-order of potency similar to the one determined by the β-lactamase reporter assay. The maximum cAMP concentration reached ∼ 11 nM in the final assay mixture. Mouse TAAR1 cells showed a much stronger response, with a maximum cAMP concentration of ∼ 70 nM in the final assay mixture, and lower EC 50 values ( Figure 3B ). Vector cells showed no response to any of the five compounds tested (results not shown). The potency of the compounds (EC 50 ) is summarized in Table 1 . For both the human and mouse receptor, a direct cAMP measurement gave the same rank-order of potency as the reporter enzyme method. The striking difference between human and mouse TAAR1 in receptor pharmacology is obvious and consistent in both assays. With mouse TAAR1, the absolute EC 50 values from the β-lactamase reporter assay are slightly lower than those from the cAMP assay, suggesting that the β-lactamase reporter assay is more sensitive, which is most likely due to the saturation of β-lactamase gene transcription at lower cAMP concentrations.
Chimaeric human TAAR1
Even though human TAAR1 demonstrated a significant response to trace amines in the cAMP and β-lactamase reporter assays, the signals were much smaller than those of mouse TAAR1, as shown in Figures 1-3 . To improve the response signal of human TAAR1, we engineered a chimaeric receptor (cTAAR1) in which the N-terminal, C-terminal and 3rd intracellular loop sequences of human TAAR1 were replaced by the corresponding mouse sequences. In the β-lactamase reporter assay, cells expressing cTAAR1 were more sensitive to the trace amines than those expressing the native human TAAR1 ( Figure 4A assay, cells expressing cTAAR1 showed a much higher maximum response than the native human TAAR1 (E max of 60 nM in Figure 4B compared with 11 nM in Figure 3A ), but similar EC 50 s for the trace amines, suggesting a higher receptor expression level or stronger coupling to G αs , or both. The rank-order of potency of the trace amines on cTAAR1, identical between the two assays, is the same as on human TAAR1 (Table 1) . These results suggest that the three domains (N-terminal, C-terminal and 3rd intracellular loop) that are replaced with the corresponding regions of the mouse receptor are not involved in ligand binding.
Identification of surrogate TAAR1 agonists
To identify synthetic agonists for TAAR1, we screened some small molecule libraries against the chimaeric and mouse receptors using the cAMP assay. These libraries included compounds of neurotransmitters, orphan ligands, endocannabinoids, inhibitors of ion channels, nuclear receptors and kinases/phosphatases. Compounds that increased intracellular cAMP concentration significantly in the primary screening were selected and further confirmed by the β-lactamase reporter assay at various concentrations. A dose-response analysis was carried out and the EC 50 of these compounds was calculated. Compounds active in either cTAAR1-or mouse TAAR1-expressing cells, but not in control vector cells, are summarized in Table 2 . It was noticed immediately that many of these compounds are derivatives of PEA, tyramine or tryptamine, but most of them are not as potent as PEA (indicated in bold). Two compounds, efaroxan and idazoxan, both potent α 2 -adrenoceptor antagonists with activity on the imidazoline receptor [25] , showed modest activity on both cTAAR1 and mouse TAAR1. Consequently, more imidazoline receptor ligands were collected and tested against TAAR1.
Imidazoline ligands as TAAR1 agonists
A panel of 19 imidazoline ligands (from Tocris) was obtained and tested against human and mouse TAAR1 using the β-lactamase reporter assay. Many of these compounds showed some activities on either cTAAR1-or mouse TAAR1-expressing cells, but not in vector cells (Table 3 ). In general, compounds displayed a higher potency (lower EC 50 ) to the mouse receptor than to the human receptor. For example, the potency of moxonidine on mouse TAAR1 was 3400-fold higher than that on cTAAR1. Surprisingly, the compound guanabenz was much more potent on human TAAR1 than most of the endogenous amines were. For mouse TAAR1, both guanabenz and cirazoline showed a much higher potency than the most potent trace amine PEA. However, detailed dose-response studies revealed that all five of the selected compounds, including guanabenz, actually had a lower efficacy (maximal response) compared with PEA in cTAAR1 cells ( Figure 5A ), indicating that guanabenz is a partial agonist of human TAAR1. This conclusion is further confirmed by the results from mouse TAAR1-expressing cells, in which all five imidazoline compounds showed significantly lower efficacy than PEA, even though both guanabenz and cirazoline showed higher potency ( Figure 5B ). The rank-order of potency of these five compounds was quite distinct between the human and mouse receptor, again indicating that these two species orthologues have major differences in the residues forming the ligand-binding sites.
DISCUSSION
Trace amines have been associated with various kinds of behavioural responses and neuropsychiatric diseases. The discovery of their cognate receptors has generated tremendous interest in gaining a better understanding of these amines and in creating therapeutic agents targeting these receptors. One of the difficulties faced in studying these receptors is the poor expression level when they are expressed recombinantly in commonly used mammalian cell lines [5, 13] . Previously, functional expression of human TAAR1 was achieved by generating a rat-human chimaeric receptor [7] , co-expressing G-proteins [19, 26] or modifying the N-terminal glycosylation site [21] . In the present paper we report the successful expression of TAAR1 by using the cell line HEK-293/CRE-bla, in which both human and mouse TAAR1 showed a moderate response to trace amine as measured by both the direct cAMP assay and the β-lactamase reporter assay. The HEK-293/CRE-bla cell line was generated for high sensitivity to receptor activation [23] and is now commercially available from Invitrogen. The functional expression of TAAR1 in HEK-293/CRE-bla cells may be due to the high expression level of G αs protein or slightly increased surface expression of the receptor or both. The response of human TAAR1 in this cell line, however, is still relatively weak compared with that of mouse TAAR1, and has limited utility in screening for novel synthetic agonists. Thus we engineered a chimaeric receptor between the human and mouse receptor based on the report that a chimaeric rat and human receptor yields a stronger response [7] . This chimaeric receptor indeed showed a much stronger response when expressed in HEK-293/CRE-bla cells. More importantly, the in vitro pharmacology of this chimaeric receptor is identical with that of the native human receptor, indicating that the ligandbinding pocket is not significantly altered. This chimaeric receptor was then used to screen a collection of small molecules, leading to the discovery that some of the existing drugs are actually agonist on TAAR1. We discovered that some agonists of the imidalozine receptor are active on TAAR1. The imidazoline receptors were initially proposed as binding sites for agents containing an imidazoline structure, such as clonidine [27] . Most of these imidazoline ligands, however, are also agonists or antagonists of the α 2 -adrenergic receptor [25, 27] . Pharmacological evidences suggest that there are at least three main classes of imidazoline receptors (I1-I3) [27, 28] . The I1 imidazoline receptor mediates the sympatho-inhibitory actions to lower blood pressure; the I2 receptor is reported to be involved in some psychiatric and neurological disorders (e.g. depression, eating disorders and Parkinson's disease); and the I3 receptor regulates insulin secretion from pancreatic β-cells. Imidazoline receptors have also been implicated in cell proliferation, regulation of body fat, neuroprotection, inflammation and some psychiatric disorders. A wide range of new agonists and antagonists have been developed with very high selectivity for imidazoline receptors. Interestingly, we found that many of these agents are also potent agonists of TAAR1 with different pharmacological profiles between the human and mouse receptor. This is the first report, to our knowledge, of characterization of imidazoline receptor ligands on trace amine receptors.
Many trace amines, such as tryptamine, had previously been suggested as endogenous imidazoline receptor agonists [29] . Actually, tryptamine displayed a micromolar affinity for imidazoline binding sites in rats and rabbits [30] . Thus it was proposed that the trace amine receptors might share common ligands and pharmacological responses with the imidazoline receptors [29] . Trace amine receptors, at least TAAR1, are unlikely to be I1-I3 imidazoline receptors based on: (i) none of the identified imidazoline binding sites turned out to be related to TAAR or even GPCRs [27] , and (ii) a few putative endogenous ligands of imidazoline receptors, such as agmatine and harmane, are not agonists for TAAR1 in our assay. It is still possible, however, that these imidazoline ligands are agonists for other TAAR members, which have no agonist identified so far. The identification of imidazoline ligands with agonist activity in trace amine receptors will further complicate the explanation of the pharmcological roles of imidazoline-like ligands, since many of these compounds are already known to be agonists or antagonists of the α 2 -adrenergic receptor [25, 27] .
The results of the present study confirmed that there are remarkable species differences with regard to the rank-order of potency of these trace amines among human, rat and mouse TAAR1 [7, 19] . Many newly identified compounds from this study also showed preferable selectivity to the mouse or human receptor. For example, idazoxan is as potent as PEA on mouse TAAR1, but almost 100-fold less potent than PEA on the human receptor. Guanabenz appears to be equally potent as PEA on the human receptor, but much more potent than PEA on the mouse receptor. Such striking receptor pharmacology difference is most likely caused by the only modest homology in amino acid sequence between human and mouse TAAR1 (77 % overall identity, with a much lower level of identity in the extracellular loops). Orthologues of other biogenic amine receptors generally share 90 % or higher sequence identity between human and rodents. The difference in receptor pharmacology between the human and rodent TAAR1 will present a major challenge to drug discovery, since compounds optimized for the human receptor may be poorly active on the rodent receptors and therefore cannot be tested in rodent models. This challenge can sometimes be overcome by replacing the endogenous receptor with the human counterpart using gene knock-in technology, or partially overcome by overexpressing the human receptor using transgenic technology.
In summary, in the present paper we report that human and mouse TAAR1 can be functionally expressed in the cell line HEK-293/CRE-bla. Direct comparison of the mouse and human receptor in this cell line showed a major difference in receptor responses to a panel of trace amines. Furthermore, we identified a few compounds as potent TAAR1 agonists. Importantly, some of these compounds are imidazoline receptor ligands. These findings not only shed light on the pharmacological species difference of TAAR1, but also raise new possibilities about the mechanism of some of the imidazoline-related agents.
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